Cytune Pharma cytunepharma.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Cytune Pharma is developing a portfolio of immunotherapeutic agents to treat primarily cancer. Cytune's compound, CYP 0150, is a human interleukin-15 linked to its effector.

Cytune Pharma is developing a portfolio of immunotherapeutic agents to treat primarily cancer. Cytune's compound, CYP 0150, is a human interleukin-15 linked to its effector.

Company (Acquired)

All investors data 6 Investors

Phone: +33 (0) 666 495 594

Fax:

7 Rue Amedee Menard

 Nantes, 44300
 France

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Cytune Pharma $8M Aug 30, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Cytune Pharma Jobs

jobs by Indeed job search

Investors

Investor Investor Type Location Participating Rounds
See all 6 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Il-15 and il-15r\alpha sushi domain based immunocytokines Jun 19, 2018 Jan 26, 2021 Patent
Il-15/il-15ralpha based conjugates purification method Mar 03, 2015 Oct 20, 2020 Patent
Il-15 and il-15r\alpha sushi domain based immunocytokines Jul 19, 2016 Apr 21, 2020 Patent
Il-15/il-15ralpha based conjugates purification method Sep 18, 2020 Application
Il-15 and il-15raplha sushi domain based modulokines Aug 08, 2014 Application
See all 8 patents